Series E brings $79mm to Nuvaira

Nuvaira Inc. (formerly Holaira; medical devices to treat obstructive lung diseases) raised $79mm in its Series E financing led by US Venture Partners, which was joined by other new backers Endeavour Vision, Qiming Venture Partners, Lightstone Ventures, and Richard King Mellon Foundation and returning shareholders Advanced Technology Ventures, Morgenthaler Ventures, Split Rock Partners, Versant Ventures, Vertex Venture Holdings, and Windham Venture Partners. The company will use the funds for the pivotal AIRFLOW-3 clinical trial of its lung denervation system required to gain FDA approval, and to create a clinical development strategy in key markets in Europe.